New immune therapy trial targets Tough-to-Treat leukemia
NCT ID NCT04690595
Summary
This is an early-stage safety study testing a new type of personalized immune cell therapy called BAFFR-CAR T cells in adults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to standard treatments. The main goals are to find a safe dose and understand the side effects. Researchers modify a patient's own immune T-cells to recognize and attack cancer cells carrying a specific marker called BAFFR.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.